OTC advisory committee
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs Advisory Committee is tentatively slated to next meet on Feb. 16-17. The committee was originally scheduled to convene in December ("The Tan Sheet" Sept. 27, p. 12), but that meeting has been canceled, in part, because of a backlog at the Office of OTC Drug Evaluation and the absence of OTC office Director Michael Weintraub, who suffered a stroke in September.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning